Reach Us +1-217-403-9671
Bioanalytical Challenges In Development Of Biosimilars | 8185
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Bioanalytical challenges in development of biosimilars

International Conference and Exhibition on Biowaivers & Biosimilars

Carmine Lanni

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.002

Biosimilars are to proteins what generics are to small molecules. However, due to the complexity of proteins especially if the protein is glycosylated, the regulatory agencies (EMA and FDA) see them as novel proteins and require that they be evaluated as such. The Opportunity with biosimilars and biobetters is that the clinical utility of the drug has been demonstrated and thus the risk is small. In addition, by manipulating the protein you have the opportunity to improve on the innovator?s drug. There are a number of opportunities as a number of biologics are going off patent. As with proteins, there are several unique challenges to supporting their development. To determine the dose and regimen, the pharmacokinetics of the protein must be demonstrated, thus this requires the development of a bioanalytical method, usually an immunoassay. This requires the appropriate selection of reagents and formats that will measure the intact drug not its metabolite or fragment. In addition, for some molecules it may be total drug, bound drug, or free drug to determine what fraction of the dose is bioavailable. The PK assay method must be able to permit demonstration of bioequivalence of the biosimilar. The inherent instability of most proteins in human matrix also requires that the molecule is stable during sample collection and processing. The mere presence of an Fc region does not ensure stability in biologic matris. In addition, the immunogenicity of the molecule must be demonstrated, requiring the design of an immunogenicity testing process. The design of the immunogenicity testing process is dependent on the risk level of and type of molecule and can be quite complex. In summary while the bioanalytical support for development of biologics is more complex than small molecules, the high probability of success makes it cost effective.
Lanni has worked for 30 years in a number of pharmaceutical, and biotechnology companies, as well as CROs in drug discovery (10 years) and Development and GLP bioanalysis (20 years). These companies Include, RW Johnson Research Institute, Abbott Laboratories, Amgen Inc, Allergan, Quest Diagnostics Clinical Trials and MPI Research he is currently Chief Scientific Officer and Co-founder of a Bioanalytical CRO specializing in biologics called Biologic Development Services. Lanni received his doctorate in biochemistry and biophysics from the Medical College of Virginia where his research focused on phospholipid metabolism of alveolar macrophages. His postdoctoral work, conducted over two years at the Department of Pathology at the University of Connecticut Health Center, involved the activation of phospholipid metabolizing enzymes during an inflammatory response. Lanni has over 50 publications and has chaired several workshops and conference sessions at national and international conferences. He has participated in the development on five molecules in a variety of therapeutic areas that have obtained FDA approval.